News

Cupron Performance Additives Announces New Applications for Cupron Sinerji™

Innovative antimicrobial solutions provider Cupron®, doing business as Cupron Performance Additives, announces expanded functionality for its recently introduced antimicrobial platform technology Cupron Sinerji.  Initially engineered as a copper-based formulation, Cupron® has now extended Cupron Sinerji’s  performance, cost, and color advantage to all metal ion chemistries commonly used for antimicrobial purposes.  Specifically, Cupron’s new platform technology delivers improved antimicrobial performance across commoditized antimicrobial metal ion types – copper, silver and zinc.

Cupron Sinerji incorporates adjuvants into the metal ion-based formulations, resulting in a custom, flexible technology engineered to harness synergistic effects to meet a wide range of product protection and antimicrobial performance objectives – from US EPA Treated Article Exemptions to unique and differentiated Public Health Claims.  FDA-regulated products may also incorporate customized Cupron Sinerji formulations.

Utilizing adjuvants, the technology delivers heightened efficacy against various organisms, including mold and mildew, improves color performance and increases manufacturing yields. It offers an efficient and adaptable solution for numerous markets and applications, demonstrating its versatility and innovative potential across all polymers and organisms.

“Expensive silver additives cause many brands to limit the amount used during manufacturing, diminishing the antimicrobial potency of the final products,” said Chris Andrews, CEO of Cupron Performance Additives.

Cupron Sinerji also imparts several non-cost benefits as well to a range of metal ion offerings: color flexibility, color stability, production efficiency and an improved sustainability profile across a range of substrates. With Cupron Sinerji, our partners will re-evaluate the economics and applications associated with microbial control and management. We are pleased to be the reason the market will expect more from antimicrobial additives.”

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin